Comparing injection vs. radiation for eye lymphoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial compares two treatments for a slow-growing eye lymphoma called MALT lymphoma: a targeted injection (rituximab) directly into the tumor versus low-dose radiation. The goal is to see which is safer and works better, while avoiding whole-body side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have a type of eye lymphoma called MALT lymphoma that has not spread to the back of the eye socket
- You have not had previous radiation, chemotherapy, or other drugs for this lymphoma
- You do not have other serious eye problems like glaucoma, cataracts needing surgery, or retinal disease
- You are not pregnant, breastfeeding, or have serious health conditions like heart, kidney, or other cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for a type of lymphoma in the eye area: injecting a drug called rituximab directly into the tumor versus using targeted radiation therapy. The goal is to see which treatment works better with fewer side effects.
This trial compares two approaches: continuing regular infusions of a drug called rituximab (a type of immunotherapy) versus simply watching and waiting, for people with a slow-growing lymphoma who cannot have chemo. Rituximab may help keep the lymphoma under control for a longer time, but it's not yet known which approach is better.
This trial tests a short course of low-dose radiation (12 Gy in 6 sessions) to treat slow-growing lymphoma in the eye area. It aims to control the lymphoma while minimizing side effects.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
This trial tests a treatment for primary vitreoretinal lymphoma, a rare eye cancer. It aims to see if the drug methotrexate can help patients with this condition.
Hear when a new Primary Ocular Adnexal MALT Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.